型号:
产品价格:电议      采购度:1317      原产地:美洲
发布时间:2022/1/21 15:56:25 所属地区:国外 国外
简要描述:
Laduviglusib (CHIR-99021) 是一种有效的选择性 GSK-3α/β 抑制剂,IC50 为 10 nM 和 nM。Laduviglusib 对 GSK-3 的选择性比 CDC2,ERK2 和其他蛋白激酶高 500 倍以上。Laduviglusib 还是一种有效的 Wnt/β-catenin 信号通路激活剂。CHIR-99021 可增强小鼠和人类胚胎干细胞的自我更新。Laduviglusib 能诱导细胞自噬 (autophagy)。
标签:CHIR-99021
产品详情
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 252917-06-9
MCE 站:Laduviglusib
产品活性:Laduviglusib (CHIR-99021) 是一种有效的选择性 GSK-3α/β 抑制剂,IC50 为 10 nM 和 6.7 nM。Laduviglusib 对 GSK-3 的选择性比 CDC2,ERK2 和其他蛋白激酶高 500 倍以上。Laduviglusib 还是一种有效的 Wnt/β-catenin 信号通路激活剂。CHIR-99021 可增强小鼠和人类胚胎干细胞的自我更新。Laduviglusib 能诱导细胞自噬 (autophagy)。
研究领域:PI3K/Akt/mTOR | Stem Cell/Wnt | Autophagy
作用靶点:GSK-3 | Wnt | β-catenin | Autophagy
In Vitro: Laduviglusib (CHIR-99021) inhibits human GSK-3β with Ki values of 9.8 nM. Laduviglusib is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that Laduviglusib specifically inhibits GSK3β (IC50=~5 nM) and GSK3α (IC50=~10 nM), with little effect on other kinases. In the presence of Laduviglusib the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib with an IC50 of 4.9 μM.
In Vivo: In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration. Laduviglusib (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. Laduviglusib treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h.
相关产品:Bioactive Compound Library Plus | Kinase Inhibitor Library | PI3K/Akt/mTOR Compound Library | Stem Cell Signaling Compound Library | Wnt/Hedgehog/Notch Compound Library | Anti-Cancer Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Reprogramming Compound Library | Diabetes Related Compound Library | Oxygen Sensing Compound Library | Glycolysis Compound Library | Cytoskeleton Compound Library | Chemical Probe Library | Anti-Alzheimer's Disease Compound Library | Neuroprotective Compound Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Neurodegenerative Disease-related Compound Library | Transcription Factor Targeted Library | Glucose Metabolism Compound Library | XAV-939 | IWR-1 | IWP-2 | ICG-001 | SB 216763 | Wnt-C59 | Pyrvinium pamoate | Salinomycin | LY2090314 | SKL2001 | BML-284 | Tideglusib | Heparan Sulfate | Laduviglusib monohydrochloride | AR-A014418 | TDZD-8 | Adavivint | TWS119 | NCB-0846 | Kenpaullone | GSK 3 Inhibitor IX | Toxoflavin | MSAB | HLY78 | iCRT3 | Wogonin | FH535 | LF3
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 染料试剂 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
更新时间:2024/1/2 10:19:40
留言咨询
温馨提示
1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。
相关新闻
相关产品